Changes in psychic and somatic well-being and cognitive capabilities of peri- and postmenopausal women after the use of a hormone replacement drug containing estradiol valerate and levonorgestrel.
A multicenter, prospective, open-label postmarketing surveillance study examined to what extent 2-month oral hormone replacement therapy (estradiol valerate and levonorgestrel; Klimonorm) could produce changes in psychosomatic well-being, self esteem and cognitive capabilities in 78 peri- and postmenopausal women. The women included were 42-58 years of age and had approached the physician due to climacteric symptoms. The following tests were used: Kupperman index, Menopause Rating Scale (MRS II), General Depression Scale (ADS), Zerssen's Symptom List (B-L), Frankfurt Self-Concept Scales (FSAL, FSAP, FSEG, FSSW), Digit Symbol Substitution Test (DSST), d2 Test of Attention and Number Square Test. The results showed a clear improvement in subjective psychosomatic well-being and improvements to a lesser extent in the concentration and cognitive capabilities in women in the third treatment cycle.
Rudolph
I
I
Jenapharm GmbH & Co. KG, Jena, Germany.
Zimmermann
T
T
Kaminski
K
K
Jandova
K
K
Borovsky
B
B
Ahrendt
H J
HJ
Golbs
S
S
D000284:Administration, Oral; D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D003071:Cognition / Q000187:drug effects*; D003863:Depression / Q000188:drug therapy; D004338:Drug Combinations; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy / Q000523:psychology*; D006801:Humans; D016912:Levonorgestrel / Q000627:therapeutic use*; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects* / Q000523:psychology; D017697:Premenopause / Q000187:drug effects* / Q000523:psychology; D011358:Product Surveillance, Postmarketing; D011594:Psychometrics; D012649:Self Concept
D004338:Drug Combinations; C097275:klimonorm; D004958:Estradiol; D016912:Levonorgestrel